Olaparib after surgery resulted in durable response rates in patients with high-risk biochemically recurrent prostate cancer ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Lynparza is approved in 64 countries, including those in the EU, for the maintenance treatment of platinum-sensitive relapsed ovarian cancer regardless of BRCA status.

Battle lines are being drawn up in metastatic castration-resistant prostate cancer (mCRPC), with AstraZeneca and Merck & Co’s market-leading PARP inhibitor Lynparza firmly in the sights of newer ...

The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics. Each of their ...

Lynparza, Calquence and Truqap. At AstraZeneca, Dr. Fawell also helped build the company’s targeted protein degradation ...

Here are 10 of the best health care stocks to buy in 2024, according to CFRA analysts: *As of Sept. 10 close. Based on ...

The new medication is a targeted therapy for people with BRCA1 and BRCA2 mutations called Lynparza which aims to stop recurrence. Being done with chemo and radiation marks the end of chapter one.

The European Commission approved a combination therapy of Imfinzi and Lynparza to treat certain patients with primary advanced or recurrent endometrial cancer. This approval is based on data from ...

Most patients with ovarian cancer are diagnosed at late stage as symptoms at early stages are minimal making it difficult to differentiate from common diseases. Once patients reach these late stages, ...